KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$61.8 million.

  • Supernus Pharmaceuticals' Free Cash Flow fell 21589.08% to -$61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.8 million, marking a year-over-year decrease of 5887.16%. This contributed to the annual value of $171.2 million for FY2024, which is 5490.8% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Free Cash Flow is -$61.8 million, which was down 21589.08% from $58.1 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Free Cash Flow ranged from a high of $71.4 million in Q2 2022 and a low of -$61.8 million during Q3 2025
  • Its 5-year average for Free Cash Flow is $29.0 million, with a median of $36.2 million in 2021.
  • In the last 5 years, Supernus Pharmaceuticals' Free Cash Flow soared by 131547.38% in 2023 and then plummeted by 21589.08% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Free Cash Flow (Quarter) stood at $48.8 million in 2021, then plummeted by 43.13% to $27.7 million in 2022, then skyrocketed by 62.25% to $45.0 million in 2023, then dropped by 1.78% to $44.2 million in 2024, then crashed by 239.83% to -$61.8 million in 2025.
  • Its last three reported values are -$61.8 million in Q3 2025, $58.1 million for Q2 2025, and $30.3 million during Q1 2025.